
Please try another search
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Man Kin Tam | 45 | 2019 | CFO & Director |
Aurelien Marabelle | - | 2023 | Member of Scientific & Strategic Advisory Board |
Peter P. Luo | 57 | 2011 | Co- Founder, Chairman, CEO and President of R&D |
Yiu Leung Cheung | 64 | 2021 | Independent Director |
Robert Jay Spiegel | 75 | 2021 | Member Scientific and Strategic Advisory Board |
Stanley R. Frankel | 65 | 2021 | Member Scientific & Strategic Advisory Board |
Steven Alan Fischkoff | 72 | 2021 | Member of Scientific & Strategic Advisory Board |
David R. Gandara | 76 | 2022 | Member Scientific & Strategic Advisory Board |
Li Zhu | 75 | 2023 | Independent Director |
Ulf Grawunder | 59 | 2024 | Independent Director |
Heinz-Josef Lenz | 65 | 2024 | Member of Scientific & Strategic Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review